Role of CDKN1C in hypopharyngeal cancer
| Project/Area Number |
17K11414
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Miyagi Prefectural Hospital Organization Miyagi Cancer Center |
|---|
Principal Investigator |
Imai Takayuki 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 特任研究員 (80408583)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
望月 麻衣 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 研究員 (40726303)
|
|---|
| Project Period (FY) |
2017-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 頭頸部がん / 扁平上皮癌 / 頭頸部癌 / 頭頚部癌 / CD271 / CDKN1C / 細胞増殖 / 下咽頭癌 |
|---|
| Outline of Final Research Achievements |
Head and neck cancer is a common cancer worldwide and its incidense is slowly increasing in Japan. Previously we investigated the CD271-CDKN1C pathway in hypopharyngeal cancer, and in this study we newly established an anti-CD271 antibody for treatment. The antibody exerts ADCC activity and shows a tumor-reducing effect in vivo. These results demonstrate the feasibility of antibody treatiment targeting CD271.
|
| Academic Significance and Societal Importance of the Research Achievements |
私たちは頭頸部がんの新規治療法確立のために、がん幹細胞マーカーであるCD271に対する抗体を作成し、治療できるか検討した。その結果、担癌マウスにおいて抗体投与群では腫瘍縮小効果を得られた。今後はさらに改善を行い、実用化を目指す。
|
Report
(5 results)
Research Products
(7 results)
